World's Largest Cancer Charity Invests in Dotmatics Solutions

BISHOPS STORTFORD, UNITED KINGDOM, Sep 29, 2011 (MARKETWIRE via COMTEX) -- Dotmatics Ltd, a global provider of informatics software and services, announced today that UK based Cancer Research Technology (CRT) has invested in the Dotmatics platform to bring efficiency to their current research processes. CRT, the technology development and commercialisation arm of Cancer Research UK, the world's leading cancer charity has deployed Dotmatics tools to improve the analysis of their data and accelerate the drug discovery process.

Researchers at CRT are now able to enhance their research workflow by utilising Dotmatics' data visualisation and analytics tool Vortex and Browser for querying and reporting of scientific data. Dr Fabrice Turlais, group leader HTS and compound management at CRT commented, "The functionality provided by Dotmatics software gives us solutions to support our research and helps us mine our data in a way that was not possible before, this will enable us to execute our drug discovery projects better and faster".

"Our philosophy has always been to provide powerful, easy-to-use tools, to scientists to enable them to make the most of their data", said Dr. Stephen Gallagher, CEO and Founder of Dotmatics. "Cancer Research Technology is engaged in critical research and we are delighted to be enabling non-profit organizations to advance scientific discoveries".

About Dotmatics

Dotmatics has rapidly emerged as a preferred informatics supplier to many of the top global pharmaceutical, biotechnology, and academic organisations. Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, managed and shared within companies. Dotmatics has significant expertise in chem- and bio- informatics techniques including chemical databases, SAR analysis, data management and data visualization. A privately owned company, Dotmatics was founded in 2005 and has its head office based south of Cambridge, UK.

About Cancer Research Technology

Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research.



Contacts:
Enquiries: Dotmatics Limited
The Old Monastery, Windhill
Bishops Stortford, Herts, CM23 2ND, UK
+44(0)1279 654 123
+44(0)1279 653 088 (FAX)
info_at_dotmatics_dot_com

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.